Table 2.
CDAD symptom improvement with rifaximin 1200 mg/day for 10 days.
| Patient | Symptom resolution with rifaximin | TLUS, h* | Followup stool EIA† | Relapse at 2 weeks | Relapse (followup, d) |
|---|---|---|---|---|---|
| (1) | Yes | 84 | NA‡ | No | No (261) |
| (2) | Yes‡ | 282 | Positive | Yes | NA |
| (3) | Yes | 128 | Negative | No | No (194) |
| (4) | Yes | 108 | Negative | No | Yes (52) |
| (5) | Yes | 187 | Negative | No | No (162) |
| (6) | Yes | 96 | Positive | No | No (149) |
| (7) | Yes | 192 | Negative | No | No (160) |
| (8) | Yes | 131 | Negative | No | No (36) |
CDAD: Clostridium difficile-associated diarrhea; EIA: enzyme immunoassay; NA: not applicable; TLUS: time to last unformed stool.
*From ingestion of first rifaximin tablet. †Obtained on day 10 following initiation of rifaximin therapy. ‡Followup stool sample not provided. ‡Symptom resolution occurred 2 days after completing the 10-day course of therapy.